ALFA Finder| Revenue growth | Q2 revenue ₹511 Cr, up 23% YoY; H1 ₹981 Cr, up 25%. |
|---|---|
| Margins | Q2 operating EBITDA margin 23.5%, up 390bps YoY; mature cohort 29.6%. |
| Demand visibility | Occupancy up to 73% H1 from 59%; Rajasthan state scheme suspended. |
| Management confidence | Confident; declined numeric guidance, flagged Udaipur softness. |
Growth
Operating EBITDA margin up 390bps to 23.5%; growth led by new hospitals (+139%) and volume (inpatient +27.3%). Price split undisclosed.
Outlook
No numeric guidance; beds rise to ~1,800 by H2 FY27, with Gurugram (300) and Ludhiana (500) to follow.
Risks
Receivables ₹350 Cr to ₹518 Cr (Mar–Sep), H1 operating cash flow only ₹68 Cr; Rajasthan government scheme suspension hits Udaipur.
Earnings Call Transcript filed with NSE, NSE: PARASHLTH. Summary written with AI assistance from the document.
Paras Healthcare Ltd: key numbers
- Share price
- ₹843.00
- Market cap
- ₹9,121 Cr
- Revenue (annual)
- ₹1,606 Cr
- Net profit (annual)
- ₹43.83 Cr
- Promoter holding
- 63.95%
- FII holding
- 11.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Paras Healthcare Ltd
All →Paras Healthcare Management Change
Paras Healthcare's board confirmed continuation of Mr. Kabir Kishin Thakur as Non-Executive Non-Independent Director under Regulation 17(1D), effective 5 November 2026. The outcome was reported after a board meeting held the same day.
Paras Healthcare Results Update
Paras Healthcare reported Q2 FY27 revenue of Rs. 510.9 crore, up 22.8% YoY, through a press release. These are its first results since its October 2026 listing.
Paras Healthcare Q2 FY27 Results: Net Profit ₹40.4 Cr, Up 225.8% YoY
Paras Healthcare Ltd reported revenue from operations of ₹510.9 Cr (+22.8% YoY) and net profit of ₹40.4 Cr (+225.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹40.4 Cr · +225.8% YoY
Paras Healthcare Board Meeting Date
Paras Healthcare will hold a board meeting on 5 November 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after the results are declared.
Paras Healthcare Capital Structure Change
360 ONE funds disclose conversion of 78.82 lakh pre-IPO unlisted Paras Healthcare shares into listed shares at 7.28% stake. No new shares were acquired; the holding remained unchanged post-listing.
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.